ReproGo Ltd.
ReproGo Ltd, a Deep Tech startup originating from Queen's University Belfast, is at the forefront of advanced stem cell-based technology with a mission to drive the adoption of eco-friendly biomanufacturing practices in regenerative medicine.
Company Overview and History:
ReproGo Ltd, a Deep Tech startup originating from Queen's University Belfast, is at the forefront of advanced stem cell-based technology. Founded and led by CEO Dr. Sophia Kelaini and co-founder Prof. Andriana Margariti, ReproGo boasts a rich research history spanning nearly two decades. The company's core focus lies in cell reprogramming and differentiation, with a mission to drive the adoption of eco-friendly biomanufacturing practices in regenerative medicine.
ReproGo concentrates its research and development efforts on vascular and cardiovascular diseases, addressing pressing health concerns such as diabetes, heart disease, and chronic wounds. The company collaborates with an award-winning team to develop a patent-pending technique that streamlines the creation of vascular cells and advanced organoids. This innovation positions ReproGo as a pioneer in the field.
Problem Identified
The company identified vascular dysfunction and reduced blood flow as major contributors to various diseases and mortality, including diabetic complications, stroke, heart disease, and chronic wounds. ReproGo strategically targets these challenges, aiming to make a significant impact in the field of vascular diseases.
Solution Developed
ReproGo has introduced an Advanced Therapy Medicinal Product (ATMP) for vascular treatment, currently pending patent filing. This ground breaking product allows to produce high-quality stem cell-derived vascular cells and organoids, tailored to meet the specific needs of customers. What sets ReproGo apart is its unique manufacturing process, characterized by being xeno-free, shorter, and regulatory-friendly. This approach aligns with environmentally conscious practices and reduces resource consumption by requiring a lower cell dose and eliminating purification steps.
The company's vascular cells exhibit remarkable purity and longevity, promoting sustainability by minimizing waste. Unlike many existing solutions, ReproGo's cells can restore vascular function and are amenable to gene manipulation, addressing not only symptoms but also the underlying causes of vascular diseases.
Steps in the Commercialisation journey
One of the key first steps to commercialisation for ReproGo was the team’s acceptance onto the ICURe (Innovation to Commercialization of University Research) Programme in 2021. This programme provided invaluable guidance and resources to transition from academia to the commercial market successfully. Through ICURe, ReproGo refined its business strategy, identified target markets, and honed its value proposition.
In 2022, ReproGo expanded its horizons by participating in the Global Business Innovation Programme (GBIP) in Canada, focusing on the biomanufacturing of advanced therapies. In the same year, ReproGo reached the regional semi-finals of the SeedCorn Competition in 2022. This recognition validated the company's viability and innovation in the biotechnology industry.
In 2023, ReproGo availed of the Kickstart Programme (a follow-on from ICURe) to advance thinking on marketing its pioneering vascular cell therapy. ReproGo was also shortlisted for the MIT REAP NI Deep Tech Accelerator programme organised by QUBIS, which has helped them to focus on building the team, devise a strategy for Intellectual Property, implement regulatory processes and prepare for Investor Readiness including pitching.
Skills and Funding Development:
ReproGo has been actively honing its skills in pitching and grant writing, gaining a deeper understanding of the regulatory processes involved in cell therapies in both the UK and international markets.
What next for ReproGo?
ReproGo’s innovative approach and dedication to sustainability, position the company for continued growth and success in the field of regenerative medicine and vascular therapies. ReproGo is poised to make a significant impact on the treatment of vascular diseases and chronic wounds while contributing to patient-centric solutions and the advancement of sustainable biomanufacturing practices.